Note 9 - Segment Reporting

6 Months Ended

Jun. 30, 2019

Notes to Financial Statements

Segment Reporting Disclosure [Text Block]

9

.      

Segment Reporting

The Company has

two

reportable segments, which are the same as its operating segments:

The Clinical Development Segment is developing autologous (utilizing the patient’s own cells) stem cell-based therapeutics that address significant unmet medical needs for applications within the vascular, cardiology and orthopedic markets.

The Device Segment is a pioneer and market leader in the development and commercialization of automated technologies for cell-based therapeutics and bio-processing.

The following table summarizes the operating results of the Company’s reportable segments:

	Three Months Ended June 30, 2019
	Clinical Development			Device		Total
Net revenues	$	44,000		$	4,261,000	$	4,305,000
Cost of revenues		57,000			2,297,000		2,354,000
Gross profit		(13,000	)		1,964,000		1,951,000
Operating expenses		483,000			1,730,000		2,213,000
Operating loss	$	(496,000	)	$	234,000	$	(262,000	)
Depreciation and amortization	$	75,000		$	115,000	$	190,000
Stock-based compensation expense	$	59,000		$	66,000	$	125,000
Goodwill		--		$	781,000	$	781,000
Total assets	$	4,412,000		$	12,120,000	$	16,532,000

	Three Months Ended June 30, 2018
	Clinical Development			Device			Total
Net revenues	$	46,000		$	1,958,000		$	2,004,000
Cost of revenues		49,000			1,592,000			1,641,000
Gross profit		(3,000	)		366,000			363,000
Operating expenses		28,408,000			2,460,000			30,868,000
Operating loss	$	(28,411,000	)	$	(2,094,000	)	$	(30,505,000	)
Depreciation and amortization	$	69,000		$	105,000		$	174,000
Impairment charges	$	27,202,000		$	--		$	27,202,000
Stock-based compensation expense	$	122,000		$	41,000		$	163,000
Goodwill	$	500,000		$	781,000		$	1,281,000
Total assets	$	12,808,000		$	10,435,000		$	23,243,000

	Six Months Ended June 30, 2019
	Clinical Development			Device			Total
Net revenues	$	55,000		$	7,213,000		$	7,268,000
Cost of revenues		100,000			3,957,000			4,057,000
Gross profit		(45,000	)		3,256,000			3,211,000
Operating expenses		955,000			3,423,000			4,378,000
Operating loss	$	(1,000,000	)	$	(167,000	)	$	(1,167,000	)
Depreciation and amortization	$	169,000		$	233,000		$	402,000
Stock-based compensation expense	$	113,000		$	93,000		$	206,000
Goodwill	$	--		$	781,000		$	781,000
Total assets	$	4,412,000		$	12,120,000		$	16,532,000

	Six Months Ended June 30, 2018
	Clinical Development			Device			Total
Net revenues	$	108,000		$	3,763,000		$	3,871,000
Cost of revenues		120,000			3,036,000			3,156,000
Gross profit		(12,000	)		727,000			715,000
Operating expenses		29,588,000			4,889,000			34,477,000
Operating loss	$	(29,600,000	)	$	(4,162,000	)	$	(33,762,000	)
Depreciation and amortization	$	137,000		$	196,000		$	333,000
Impairment charges	$	27,202,000		$	--		$	27,202,000
Stock-based compensation expense	$	220,000		$	80,000		$	300,000
Goodwill	$	500,000		$	781,000		$	1,281,000
Total assets	$	12,808,000		$	10,435,000		$	23,243,000